During a discussion on the next frontier of medicine for cold agglutinin disease, stakeholders react to the rationale for studying newer, novel complement-targeted therapies. Neil Minkoff, MD: Let me ...
The complement system is activated in many rheumatic diseases, as evident from deposition of activation fragments in affected tissue, decreased residual complement function and increased levels of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results